摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(1H-Indol-2-yl)-5-fluoro-1H-indazole | 503045-67-8

中文名称
——
中文别名
——
英文名称
3-(1H-Indol-2-yl)-5-fluoro-1H-indazole
英文别名
5-fluoro-3-(1H-indol-2-yl)-1H-indazole
3-(1H-Indol-2-yl)-5-fluoro-1H-indazole化学式
CAS
503045-67-8
化学式
C15H10FN3
mdl
——
分子量
251.263
InChiKey
XVQBKJOGUAKOEG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    44.5
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    potassium carbonate 作用下, 以 四氢呋喃甲醇 为溶剂, 生成 3-(1H-Indol-2-yl)-5-fluoro-1H-indazole
    参考文献:
    名称:
    Identification of potent ITK inhibitors through focused compound library design including structural information
    摘要:
    A series of novel compound libraries inhibiting interleukin-2 inducible T cell kinase (ITK) were designed, synthesized and evaluated. In the first design cycle two library scaffolds were identified showing low micromolar inhibition of ITK. Further iterative design cycles including crystal structure information of ITK and structurally related kinases led to the identification of indolylindazole and indolylpyrazolopyridine compounds with low nanomolar ITK inhibition. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.09.119
点击查看最新优质反应信息

文献信息

  • Tyrosine kinase inhibitors
    申请人:Arrington L. Kenneth
    公开号:US20050070546A1
    公开(公告)日:2005-03-31
    The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    本发明涉及抑制、调节和/或调节酪氨酸激酶信号传导的化合物,含有这些化合物的组合物,以及使用它们治疗哺乳动物中的酪氨酸激酶依赖性疾病和病状的方法,例如血管生成、癌症、肿瘤生长、动脉硬化、年龄相关性黄斑变性、糖尿病视网膜病变、炎症性疾病等等。
  • Differentiation modulating agents and uses therefor
    申请人:Prins Bernhard Johannes
    公开号:US20050282733A1
    公开(公告)日:2005-12-22
    The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
  • DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR
    申请人:Prins Johannes Bernhard
    公开号:US20120059047A1
    公开(公告)日:2012-03-08
    The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
  • US7101884B2
    申请人:——
    公开号:US7101884B2
    公开(公告)日:2006-09-05
查看更多